We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Combating Infectious Diseases Key Focus of AACC

By LabMedica International staff writers
Posted on 03 Aug 2017
At the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services, over 750 exhibitors displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation, with the focus being largely on speed and effectiveness in infectious disease detection.

According to Kalorama Information, (New York, NY, USA), an independent medical market research firm, diseases caused by infection are among the largest and most competitive markets for in vitro diagnostics (IVD) instruments, kits and reagents. The 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from July 30–August 3, saw important product announcements for early and accurate detection for the treatment of infectious diseases.

Some of the product announcements at the event included a new method for detecting 5 gram-negative bacteria using genoproteomic peptide marker analysis on a combined MS/LC system. Additionally, Ortho Clinical Diagnostics showcased its Vitros Immunodiagnostic Products human immunodeficiency virus (HIV) combo assay for use on the Vitros 3600 immunodiagnostic system. A fourth-generation HIV assay, the Vitros HIV combo is designed to detect acute HIV-1 infection earlier than previous generations of HIV assays.

Further, Aalto Bio Reagents, a developer and provider of raw materials to the in- vitro diagnostics industry and to research laboratories globally, announced their first-to-market recombinant Yellow Fever Virus (YFV) protein. Also, Seegene Inc. announced a Random Access System, which can provide order-to-report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, regardless of specimen type or assays.

Related Links:
Kalorama Information

Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Immunofluorescence Analyzer
IFA System

Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
PURITAN MEDICAL